New Type of Hypertension Treatment Effective and Well Tolerated
Data emerging from early studies of aliskiren, a new type of treatment for hypertension, indicate that the new drug is effective as a single treatment for patients with mild-to-moderate uncomplicated essential high blood pressure. Results of initial randomized controlled clinical trials also suggest that the new medication is well tolerated and that patients exhibit good adherence to the once-a-day oral medication.
(I-Newswire) - The evaluation appears in the premier issue of the journal Core Evidence, the first international peer-reviewed publication to assess medications by critically evaluating evidence on clinical effectiveness and outcomes.
Hypertension affects approximately 50 million people in the USA and about 1 billion people worldwide, and the World Health Organization ( WHO ) estimates that there are 7.1 million deaths each year ( 13% of all mortality ) due to complications of hypertension.
“Despite the availability of many effective, well-tolerated drugs, a significant portion of treated hypertensive patients remain uncontrolled and face serious morbidity and mortality as a consequence,” wrote Doris Peter, PhD, the journal's Editor for North America, who authored the review. “The current challenges in the drug treatment of hypertension include adherence to therapy and the need for most patients to take more than one drug to control their hypertension,” Dr Peter said.
Current drug therapies for hypertension include diuretics, beta blockers, angiotensin-converting enzyme ( ACE ) inhibitors, aldosterone receptor blockers ( ARBs ), calcium channel blockers, and alpha-1 blockers, used individually and in various combinations.
Aliskiren, under development by Novartis, is the first in a new class of antihypertensive drugs called renin inhibitors. Renin is an enzyme which controls the formation of a substance called angiotensin II, the key mediator in the regulation of body fluid volume and blood pressure.
Aliskiren, which has not yet been approved by the US Food and Drug Administration, currently is in phase III trials as a stand-alone therapy and in phase II as combination therapy in patients with mild-to-moderate hypertension, and in phase II trials in patients with diabetic nephropathy.
The Core Evidence review of available phase II data concludes that there is now good evidence that as a stand-alone therapy aliskiren reduces blood pressure significantly compared with placebo and is as effective as two commonly prescribed ARBs with a similar tolerability profile. “For patients whose blood pressure can be controlled with single-agent therapy, aliskiren may offer another well-tolerated, effective alternative,” the review concluded.
The article also noted that, although further examination is needed, there is preliminary evidence from one study that adherence to aliskiren therapy is high, averaging more than 95%. The article observed that, “A good tolerability profile together with once-daily administration may be expected to positively influence adherence and quality of life, both of which can be significant barriers to effective disease management in patients with hypertension.”
However, the review also noted that, “most patients with hypertension eventually need a second antihypertensive drug” and although “there is some evidence that aliskiren combined with an ARB is effective in reducing blood pressure,” the use of aliskiren in combination therapy cannot be recommended without further study.
Studies of Renin-Inhibitor “Aliskiren” Are Reviewed in Premier Issue of “Core Evidence” First International Peer-Reviewed Journal Using Evidence-Based Measures to Evaluate Drugs
Published by Core Medical Publishing Ltd coremedicalpublishing.com ), a new company with offices in Manchester, UK and New York, Core Evidence is the first international peer-reviewed journal to rigorously evaluate the evidence for rational drug selection based on outcomes central to informed medical decision-making, with the goal of improved quality of care. Core Evidence is available in print and/or online formats. For subscription information, call toll-free 866-246-3817 or email custserv@coreevidence.com
If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
Immerse yourself in mystery and magic with two exciting new casual games from Focus Multimedia and Big Fish Games Studios, one of the world’s leading casual game developers. Hidden Expedition Titanic and Azada join Focus’ popular Revival range of super-budget price games and are available in a store near you.
Edraw Max enables students, teachers and business professionals to reliably create and publish kinds of diagrams to represent any ideas. With large pre-drawn libraries and more than 4600 vector symbols, drawing couldn't be easier!
New range of cards launched to make you the cover star.Hallmark Cards in partnership with OK Magazine has launched an exclusive and exciting new range of greeting cards that gives people the chance to give family and friends the A-List treatment.
Many people choose not to pursue an accident claim. The reasons range from knowing the insurance company will settle; to they don't want the legal hassles and expense.
Many individuals and businesses have always purchased their personal computers from a well-known provider to pre-conceived specifications. Increasingly...
The effectiveness of SEO and PPC Services are directly related to the quality and quantity of the performance data that they have to work with. If you are seeking assistance in achieving a higher ranking on search engine results, then we suggest you visit RankYourWebsites.com, specialist in this area. If you have found your attempts at optimization to prove fruitless, the representatives at RankYourWebsites.com will have a solution to increase your traffic.
http://www.vineyardsforsalein.com/ - online island vineyard for sale, vineyard for sale paso, texas vineyard for sale, washington vineyard for sale, tuscany vineyard for sale, vineyard for sale santa, vineyard for sale California
Mark Flanagan, Managing Director of Manchester health and safety, food safety and fire safety consultancy, Shieldyourself, discussed the Scores on the Doors scheme when he made a guest appearance on the BBC’s 5 Live Radio Show recently.
